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ABSTRACT  
 
Skeletal muscle is the most abundant human tissue; therefore, an unlimited 
availability of myogenic cells is relevant for regenerative medicine and drug 
development. Here we detail a protocol to derive myogenic cells from human 
embryonic stem (ES) and induced pluripotent stem (iPS) cells in three weeks. 
We also provide evidence for its extension to human iPS cells cultured without 
feeder cells. The procedure, which does not require embryoid bodies or 
prospective isolation, entails four steps with different culture densities, media and 
surface coating. Pluripotent stem cells are first differentiated into expandable 
cells resembling human mesoangioblasts. Subsequently, transient MyoD 
induction efficiently drives myogenic differentiation into multinucleated myotubes. 
Patient-specific cells obtained with this protocol have been genetically corrected 
and were proven to have therapeutic potential in dystrophic mice. This platform is 
amenable for gene and cell therapy, tissue engineering and disease modelling.  
 
 2 
INTRODUCTION  
 
Skeletal muscle regenerates after injuries or during chronic diseases such as 
muscular dystrophies. Muscular dystrophies are a heterogeneous group of 
disorders characterised by progressive muscle wasting that causes serious 
mobility and breathing impairment, leading to death in the most severe forms1.  
Regeneration relies mainly on adult stem cells called satellite cells2, which reside 
underneath the myofibres' basal lamina and generate committed progenitors 
called myoblasts. At present, there is no definitive cure available for such 
diseases, although a number of experimental treatments are undergoing pre-
clinical and clinical experimentation2,3. Among these, cell therapy aims at 
providing a non-mutated copy of the gene of interest while restoring the lost 
tissue and (ideally) its stem/progenitor cell compartment. However, despite the 
promising results obtained in murine models, clinical trials with myoblast 
transplantation in patients with muscular dystrophy indicate that their use might 
be restricted to local delivery4. Other myogenic cells can also be isolated from 
skeletal muscle2. Among them, pericyte-derived mesoangioblasts5 are a 
promising population that can be delivered systemically; they are currently 
undergoing clinical experimentation for Duchenne Muscular Dystrophy (DMD, 
OMIM #310200; EudraCT no. 2011-000176-33). Although allogeneic cell therapy 
could be a feasible option, autologous transplantation would be desirable, as it 
would avoid or reduce immune-suppressive therapy for patients. However, the 
cycles of degeneration-regeneration of dystrophic muscle challenges the 
availability and proliferation potential of tissue-derived progenitors for autologous 
therapies6-11 Additionally, the large-scale expansion required to generate 
adequate cell numbers for drug screening platforms and tissue engineering also 
challenges the proliferative potential of myogenic cells derived from adult muscle, 
posing a major hurdle for the development of successful therapeutic 
interventions. Induced pluripotent stem (iPS) cells could provide a solution to this 
limitation12. Nonetheless, safe and efficient methods to differentiate iPS cells 
towards specific cell lineages need to be developed and validated.  
 
 3 
 
In order to overcome the above-mentioned limitations, we have developed 
a protocol to differentiate human pluripotent stem cells into an expandable cell 
type similar to mesoangioblasts that efficiently generates skeletal muscle upon 
induction of the myogenesis regulator MyoD11. Pre-existing methods to generate 
vascular cells from human embryonic stem (ES) cells facilitated the initial setup 
of the protocol13. We have demonstrated that these iPS cell-derived, patient-
specific, myogenic cells can be genetically corrected, expanded in culture and 
differentiated into multinucleated myotubes in vitro, contributing to skeletal 
muscle regeneration by restoring the missing gene and protein upon 
transplantation in dystrophic animals11,14. Additionally, similarly to their tissue-
derived counterpart, also human iPS cell-derived mesoangioblast-like cells exert 
immunosuppressive effects on T cell proliferation15, a relevant finding for their 
possible use in cell therapies. Notably, when this protocol was utilised to 
differentiate mouse iPS cells, transplantation of the derived progeny resulted in 
amelioration of muscle function of the treated dystrophic mice11. 
In this paper we detail the experimental procedure that allows the 
derivation of mesoangioblast-like myogenic cells defined as HIDEMs (human iPS 
cell-derived mesoangioblast-like cells) from healthy and disease-specific human 
iPS cells. This is achieved via a stepwise differentiation process consisting of 
sequential monolayer cultures over 3 weeks. New evidence of extension of this 
procedure to human iPS cells cultured without feeder cells (feeder-free/FF 
HIDEMs) and to human ES cells (HEDEMs; human ES cells derived 
mesoangioblast-like cells) is also provided. These cells are expandable in culture 
and non-tumorigenic in vivo. Efficient myogenic differentiation is induced 
synchronously in the culture via Tamoxifen-driven activation of the myogenesis 
regulator MyoD, which is also a tumour suppressor gene16,17. Please refer to 
Figure 1 for a schematic view of the entire protocol. 
Although this method was originally established for gene and cell therapy 
of muscular dystrophies11, it is applicable to any other platform requiring large-
scale production of myogenic cells, such as high-throughput drug screening, 
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tissue engineering and regenerative medicine. Overall, its adaptability to patient-
specific iPS cells makes it relevant also for the promising area of personalised 
medicine18.  
 
Comparison with alternative protocols for derivation of myogenic cells 
from human pluripotent stem cells 
Different protocols have been developed over the past years to obtain myogenic 
cells from pluripotent stem cells. Most of them require embryoid body formation, 
transgene overexpression and/or prospective isolation. Barberi and colleagues 
derived CD73-positive mesenchymal precursors from human ES cells and then 
purified the NCAM-positive (also known as CD56) myogenic fraction19. Later, 
different groups derived myogenic cells from human pluripotent stem cells by 
means of embryoid body formation20,21, transgene overexpression (Pax720 and 
MyoD21-23) and enrichment by fluorescence activated cell sorting (FACS)20. 
Interesting results were produced by treatments with growth factors and small 
molecules24,25 but they still need to be validated with muscle function tests in 
vivo. As a general consideration, all the published protocols generate a myogenic 
cell population with variable efficiency and after a prolonged time in culture.  
Some of these alternative protocols showed convincing engraftment of human 
pluripotent stem cell-derived myogenic cells in murine skeletal muscle (e.g. 
Goudenege et al. 22); however, only Darabi and colleagues provided functional 
evidence of the therapeutic potential of human pluripotent stem cell-derived 
myogenic cells intramuscularly transplanted in dystrophic mice20 (although 
without genetic correction).  
Therefore, even if other methods are already available to generate 
myogenic cells from pluripotent stem cells, to our knowledge our protocol is at 
present the only published evidence of generation of genetically corrected 
patient-specific iPS cell-derived myogenic cells that engraft dystrophic muscle 
and differentiate into myofibres in vivo11. This feature, together with the possibility 
of locoregional intra-arterial delivery, makes these cells a possible future 
candidate for the treatment of muscle disorders such as DMD11,14. 
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From pluripotency to mesoangioblast-like cells 
Undifferentiated cultures of human ES and iPS cells represent the starting 
population of the protocol. Pluripotent cells need to be cultured under appropriate 
conditions and must not contain a significant population of differentiated cells, 
which might compromise the success of the procedure. Adequate cell 
pluripotency needs to be assessed prior to the start of the procedure as a 
prerequisite for an effective outcome. This includes expression analysis of 
pluripotency genes (e.g. Nanog, Oct3/4, Klf4) and in vitro and in vivo analysis of 
differentiation potential26 (e.g. teratoma-formation assay).  
Both feeder-dependent and feeder-free iPS cultures have been used with 
comparable results in terms of efficiency of differentiation; a few steps have been 
refined specifically for feeder-free cultures. Although some feeder cells can 
contaminate the feeder-dependent cultures in the first steps of the derivation 
protocol, they are then rapidly lost due to their mitotic inactivation and were never 
found in the final product. An overview of representative cell morphology at 
different steps is shown in Figure 2. 
In detail, feeder-dependent human iPS11 and ES cells (Shef 6 27) were 
cultured on a layer of mitomycin-treated mouse embryonic fibroblasts plated on 
Matrigel (iPS cells) or gelatin (ES cells) in KO DMEM-based medium. For 
passaging, feeder-dependent pluripotent clones were detached with a solution of 
1 mg/ml collagenase IV in KO DMEM and then split 1:3 – 1:5. Feeder-free 
human iPS cells (System Biosciences, USA #SC102A-1N; similar results have 
been obtained also with an additional line) were cultured in Essential 8 medium 
on a Geltrex matrix. For passaging, feeder-free cells were detached with 50 mM 
EDTA in PBS and subsequently passaged at a split ratio of 1:4 – 1:6. We do not 
have any reason to believe that presence or absence of a feeder layer would 
affect the derivation efficiency of mesoangioblast-like cells and the quality of the 
results, provided that the iPS cell cultures are kept under appropriate 
undifferentiated conditions.  
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The first step of the protocol entails the disaggregation of pluripotent 
colonies to single cells. According to the results obtained across more than 20 
different lines, this is the most critical step of the protocol in terms of cell survival. 
Pre-treatment of the cells with ROCK inhibitor28 significantly decreases cell 
mortality in this step of the protocol. Cell populations that are particularly 
sensitive to single-cell disaggregation might yield suboptimal results at this step 
and you might need to repeat it a few times before obtaining a satisfactory 
outcome. As a general rule, even if some cell death is present in the culture one 
day after single cell passaging, as long as the cell-plating density is appropriate, 
the results of the protocol will not be negatively affected. 
Culturing dissociated pluripotent cells on a Matrigel-coated surface 
exposes them to laminin, collagen IV, heparan sulfate proteoglycans and 
entactin/nidogen, all components of the vascular and muscle basement 
membranes29. Notably, Matrigel itself is known to promote vascular cell 
differentiation in vitro and in vivo in angiogenesis assays30,31 as well as 
differentiation of myogenic cells32. Importantly laminin and collagen IV, besides 
being the two main components of Matrigel, are produced by myoblasts and 
muscle fibroblasts and assembled on the surface of myotubes during 
differentiation33. They represent also the two main components of the 
extracellular matrix (ECM) of the muscle satellite stem cell niche34. Therefore we 
hypothesised that the exposure to the above ECM molecules at both cell 
densities and in media similar to those established for human ES differentiation 
into vascular smooth muscle cells13, could prime pluripotent cells toward the 
mesodermal, vascular and myogenic lineages. Upon transferring of the cultures 
into a medium optimised to culture human mesoangioblasts35, the above cells 
are then maintained in a status that allows their in vitro expansion. Human 
ES/iPS cells derived mesoangioblast-like cells will be referred from now on as 
HEDEMs and HIDEMs when derived from human ES or human iPS cells 
respectively. 
 
Expansion of HEDEMs/HIDEMs 
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HEDEMs/HIDEMs, the end product of this protocol, are cultured as skeletal 
muscle-derived mesoangioblasts35 and have the advantage of a robust 
expansion potential (Figure 3) before undergoing terminal differentiation, a key 
advantage over most tissue-derived adult progenitors. Cells are expanded on 
normal cell culture plastic without any coating in a MegaCell-based medium 
supplemented with nutrients and basic fibroblast growth factor (bFGF; see 
Reagents Setup for detailed medium composition). Alternatively, cells can also 
be grown using an Iscove Modified Dulbecco’s Medium (IMDM) supplemented as 
per Reagents List and Setup. Frozen stocks can be cryopreserved for short-term 
storage at -80 °C or in liquid nitrogen tanks, where they remain viable for at least 
4 years after freezing.  
 
Characterisation of HEDEMs/HIDEMs 
Specific assays are required to evaluate the quality of the derived 
HEDEM/HIDEM populations in terms of their immunophenotype and safety 
profile.  
 
Analysis of surface markers by flow cytometry 
Human ES/iPS cell differentiation with this protocol yields relatively 
homogeneous populations of mesoangioblast-like cells. For this reason we have 
not performed any prospective isolation so far. On the other hand, a retrospective 
characterisation of the cells is required to ensure that the desired cell population 
was obtained. This can be done by flow cytometry analysis once the culture is 
stabilised. Specifically, the markers routinely assessed are the following: CD13, 
CD31, CD56, CD44, CD45, CD49b, CD146, alkaline phosphatase (AP) and 
stage-specific embryonic marker 4 (SSEA4) (Figure 4). Briefly, CD146 (a 
vascular/perivascular marker in vivo), CD13, CD44 and CD49b expression is 
usually high (above 50%). CD56 (myoblast marker), CD45 (pan haematopoietic 
marker) and CD31 (endothelial cell marker) are very low or negative. AP 
detection via flow cytometry is not ideal as the antibody limits its detection to the 
membrane isoform. For this reason AP expression ranges from dim to very low. It 
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is anyway important to detect at least one of the two markers CD146 and AP. 
When AP signal is not detectable via flow cytometric analysis, we advise to 
perform an enzymatic reaction in order to detect its activity (Supplementary 
Figure 1b). SSEA4, a pluripotency associated marker, has to be negative or low. 
If cell preparations display more than 10% of positivity for SSEA4 it is of critical 
importance to perform analysis on residual retention of pluripotency by 
immunofluorescence analysis or quantitative real time PCR (as shown in11) and 
an in vivo tumorigenic assay. HIDEMs and human mesoangioblasts have also 
been shown to be positive for CD73 and CD10515, although we do not routinely 
assess expression of these two markers in our studies. For representative results 
on HIDEMs, feeder-free HIDEMs and HEDEMs please refer to Figure 4. 
 
Assessment of residual expression of pluripotency markers 
Even though assessment of surface markers by flow cytometry already provides 
indications on the possible presence of undifferentiated cells, it is good practice 
to assess HEDEMs/HIDEMs for any residual expression of pluripotency markers. 
This can be done using different techniques, such as immunofluorescence 
analysis (detailed in step 63-74 and shown in Supplementary Figure 1a) or 
quantitative real-time PCR (as shown in our previous paper11) for Oct4, Nanog, 
Sox2 and Klf4. HEDEMs/HIDEMs are expected to have very low or no 
expression of Oct4, Nanog, Sox2 and Klf4. All the analyses should be carried out 
comparing the expression of the above genes/proteins in HEDEMs/HIDEMs vs 
the parental ES/iPS cell lines. It is also useful to test by quantitative real-time 
PCR the expression of the exogenous pluripotency transgenes when integrating 
vectors are used to establish the initial iPS cell population (as shown in11).  
 
Induction of myogenic differentiation via MyoD activation 
Microarray gene expression profile of HIDEMs highlighted a remarkable similarity 
between them and skeletal-muscle derived mesoangioblasts. However, the same 
analysis also revealed that, at variance with their tissue-derived counterpart, they 
did not express key genes of the myogenic programme such as MyoD (Figure 
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S2B in16). Indeed, HEDEMs/HIDEMs are not capable of spontaneous skeletal 
myogenesis, although their potential to fuse with myotubes can be triggered upon 
co-culture with myogenic cells11. Moreover, previous work from our laboratory 
has shown that lentiviral-mediated expression of MyoD activates the myogenic 
programme in mesoangioblasts without erasing their ability to cross the vessel 
wall upon intra-arterial delivery and to contribute to the satellite cell pool8. 
Therefore HIDEMs/HEDEMs were transduced with a lentiviral vector 
encoding MyoD cDNA fused with the estrogen receptor (MyoD-ER(T)36), thus 
allowing inducible nuclear translocation of the protein from the cytoplasm upon 
Tamoxifen administration (in vitro and/or in vivo). Using this strategy we have 
reproducibly observed very efficient myogenic differentiation, with an efficiency of 
up to 90% with just two 4OH-Tamoxifen pulses in vitro. Importantly, cells with an 
integrated MyoD-ER(T) transgene but not exposed to Tamoxifen (i.e. having an 
inactive MyoD cytoplasmic protein) retain a good proliferation capacity, although 
moderately reduced compared with the parental cell line and can be expanded in 
culture (Figure 3). Upon Tamoxifen administration, MyoD-ER(T)-
HEDEMs/HIDEMs undergo robust and synchronous myogenic differentiation. 
Evaluation of the expression of myogenic differentiation markers such as myosin 
heavy chain (MyHC) by immunofluorescence staining allows assessing the 
differentiation efficiency as the percentage of nuclei inside MyHC-positive cells 
versus the total number of nuclei (Figure 5). Notably, the possible future use of 
Tamoxifen in vivo in cell therapy protocols based upon HIDEMs or MyoD-ER(T) 
will also be facilitated by its beneficial effect as a drug for DMD37. 
 
Safety profile of pluripotent stem cell-derived myogenic cells 
Now that iPS cells have entered clinical experimentation38,39, screening the pre-
clinical safety profile of ES/iPS-derived cells is particularly relevant. This analysis 
must include an assay to exclude the possibility to have a medicinal product 
harbouring tumorigenic properties. Prior to such a test, quality controls to 
evaluate genome stability of the HEDEM/HIDEM cell lines are advisable after 
completion of the commitment protocol. This can be done by karyotype analysis11 
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or by means of novel technologies such as array comparative genome 
hybridization40. 
To rule out the risk of in vivo tumorigenesis, HEDEMs/HIDEMs are 
injected subcutaneously in immunodeficient animals. It is advisable to use a 
minimum of 5 immunodeficient mice and a consistent positive control (e.g. HeLa 
cells) for each cell population tested. This assay is performed only for cell lines 
that provided satisfactory results during all the derivation and differentiation. 
Please note that all the work must be carried under an appropriate animal licence 
and the guidelines for tumorigenic assays might vary between different regulatory 
institutions. We advise to follow the “Guidelines for the welfare and use of 
animals in cancer research”41. As this is an assay based upon a xenogeneic 
transplant, it is normally carried over a period of at least 4 months of follow-up 
post-procedure, during which time animals are examined at least once a week. If 
the assay is negative (i.e. no tumour formation), the cell line can be considered 
safe for in vivo applications. Overall, we have tested 9 human pluripotent stem 
cell-derived cell lines in vivo and no tumour formation was observed (follow up ≥ 
4 months). Importantly, we have also compared HEDEMs (that are by definition 
transgene-free) and MyoD-ER(T)-HEDEMs, which only contain the integrated 
MyoD-ER(T) to exclude any possible transformation event due to insertional 
mutagenesis. We observed no tumour formation in both conditions.  
 
Level of expertise needed to implement the protocol 
The minimum skills required to implement this protocol include cell culture 
experience with human pluripotent, adherent and myogenic cells. We advise to 
outsource the production of the MyoD-ER(T) lentiviral vector if viral production is 
a technique not fully mastered in your laboratory. For the characterisation of the 
final product (HEDEMs/HIDEMs) it is required to be familiar with basic 
fluorescence microscopy and with fluorescence activated cell-sorting analyses. 
For the in vivo tumorigenic assay, approval of a specific animal licence needs to 
be in place before starting the procedure. Assessment of regenerative potential 
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can be performed by transplantation of the final cell product in mouse models of 
muscle regeneration, as we recently detailed in a specific video-protocol14. 
 
Limitations of the protocol 
Despite the high efficiency and reproducibility of our protocol in generating 
myogenic cells from human pluripotent cells, there might be some limitations to 
its use. Firstly, to induce myogenic differentiation we use an integrating lentiviral 
vector harbouring a cassette encoding for MyoD-ER(T). Based upon previously 
published transplantation experiments in immune-competent dystrophic mice 
using the same MyoD-ER(T) construct36, we do not have reasons to believe that 
the resulting fusion protein could be immunogenic for the host. Ad hoc 
immunological studies to address this issue might be necessary to translate this 
technology to the clinic. Although integrating vectors that overexpress myogenic 
factors in pluripotent or progenitor cells have been used also in other published 
protocols (e.g.20), safety concerns could arise due to their integrating nature. 
However, the potential risk of insertional oncogenesis has been drastically 
reduced with third generation self-inactivating lentiviral vectors42, which so far 
show excellent clinical safety profile43,44. Nevertheless, the risk of insertional 
mutagenesis must not be ignored. In this direction, it will be possible to screen 
transgene insertion with ad hoc vector integration analyses, leading to the 
identification of clones with so-called ‘safe harbour’ integrations43. As an 
alternative strategy, we are currently investigating the use of integration-free 
platforms such as integration-deficient lentiviral vectors 45,46 or MyoD-mRNAs 
(commercially available, Stemgent cat. no. 05-0029). Another promising non-
integrating vector to deliver MyoD-ER currently under development in our 
laboratory consists in the transfer of an engineered human artificial chromosome 
(HAC47) containing both MyoD and therapeutic genes (e.g. dystrophin in the case 
of Duchenne muscular dystrophy48; Hoshiya H. et al, unpublished data). 
Secondly, it is also important to consider that this method generates 
muscle cells without necessarily recapitulating skeletal muscle development in 
the embryo. Hence the application of this protocol might not be suitable for 
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research on specific developmental aspects of skeletal muscle. Although this 
aspect is not of primary importance for drug screening platforms (where 
efficiency of differentiation is likely to be still one of the key eligibility criteria for a 
protocol), future upgrades of this methodology will focus towards a complete 
chemically-defined, animal-component- and transgene-free protocol (e.g. 
replacement of Matrigel and integrating viral vectors). 
 
 
 
MATERIALS  
 
Reagents 
• Human pluripotent cells: healthy donor and dystrophic feeder-dependent 
human iPS cells described in11; Shef 6 human ES cells 27; feeder-free SBI 
iPSCs (System Biosciences, USA #SC102A-1N) 
• Dulbecco's Modified Eagle's medium (DMEM) (Sigma, cat. no. D5671) 
• MegaCell DMEM (Sigma, cat. no. M3942) 
• Mimimum Essential Medium alpha (MEM α), Nucleosides (Life 
Technologies, cat. no. 22571-020) 
• KO DMEM (Life Technologies, cat. no. 10829-018)  
• DMEM F12 (Gibco, cat. no. 11039-21) 
• Iscove's Modified Dulbecco's Medium (IMDM) (Sigma, cat. no. I3390) 
• Collagenase IV (Sigma, cat. no. 5138) 
• Essential 8 medium kit (Life Technologies, cat. no. A1517001)  
• Horse serum (Euroclone, cat. no. ECS0090L) 
• Foetal Bovine Serum (Life Technologies, cat. no. 10270-106) 
o CRITICAL: we encountered batch-to-batch variability, which could 
greatly affect cell proliferation. Although different sera should be 
tested and compared to find the most appropriate, extremely from 
low to absent levels of endotoxins are good indicators of high 
quality serum. 
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• Knockout Serum Replacement (Gibco, cat. No. 10828-028) 
• PBS Calcium/Magnesium free (Gibco, cat. no. 10010-015) 
• PBS tablets (Sigma, cat. no. P4417) 
• L-Glutamine (Sigma, cat. no. G7513) 
• Penicillin/Streptomycin (Sigma, cat. no. P0781) 
• 2-Mercaptoethanol (Gibco, cat. no. 31350-010) 
• Non-essential amino acid solution (Sigma, cat. no. M7145) 
• Human bFGF (Gibco, cat. no. AA 10-155) 
• Insulin-transferrin-selenium (ITS) (Gibco, cat. no. 51500-056) 
• Oleic acid (Sigma, cat. no. O1257-10MG) 
• Linoleic acid (Sigma, cat. no. L5900-10MG) 
• Iron Sulfate (e.g. Ferinsol, Mead Johnson as detailed in reagents setup; 
alternatively use Iron [II] cloride tetrahydrate from Sigma, cat no. 44939) 
• Sodium Ferric Gluconate Complex (e.g. Ferlixit, Aventis as detailed in 
reagents setup; alternatively use Iron [III] nitrate nonahydrate from Sigma, 
cat no. 254223) 
• Rock inhibitor Y27362 (Calbiochem, cat. no. 688000) 
• Grow factors-reduced Matrigel LDEV-Free (Corning, cat. no. 356231) 
• Geltrex LDEV-Free, hESC-qualified, reduced growth factor basement 
membrane matrix (Life Technologies, cat. no. A1413301) 
• EmbryoMax 0.1% (wt/vol) Gelatin Solution (Merk Millipore, cat. no. ES-
006-B) 
• Trypsin (Sigma, cat. no. T3924) 
• 0.5M EDTA, pH 8.0 (Fisher Scientific, cat. no. 10182903) 
• Paraformaldehyde (TAAB, cat. no. P001) 
o CAUTION: paraformaldehyde is extremely toxic and must be 
handled with adequate personal protective equipment under a 
chemical cabinet. 
• 4-OH Tamoxifen (Sigma, cat. no. H7904) 
• pLv-CMV-MyoD-ER(T) vector (Addgene, cat. no. 26809) 
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• MyoD-ER(T) integrating lentiviral vector carrying the pLv-CMV-MyoD-
ER(T) plasmid 
o CAUTION: production and work with viral vectors need to be 
carefully performed under appropriate regulation and must be done 
in dedicated facilities. If you are not allowed to produce viral vectors 
in your laboratory please refer to an authorised facility. If you are 
allowed to produce lentiviral vectors, the following protocol can be 
used as a reference49. 
• Bovine serum albumin (Sigma, cat. no. A7906) 
• Triton X-100 (Sigma, cat. no. T8787) 
• Donkey serum (Sigma, cat. no. D9663) 
• Donkey anti-Mouse IgG (H+L) 546 (Molecular probes, cat. no. A10036) 
• Donkey anti-Rabbit IgG (H+L) 488 (Molecular probes A21206) 
• Sterile cell culture grade water (Gibco, cat. no. 15230-089) 
• DMSO (Thermo scientific, cat. no. TS20684) 
• Isopropanol 99.5+% (Acros organic, cat. no. 389710025)  
• Ethanol (Acros organic, cat. no. 615095000) 
• Trypan blue (Sigma, cat. no. T8154) 
• Fluorescence mounting medium (Dako, cat. no. S3023) 
• Mouse anti SSEA 4, PE conjugated (BD Biosciences, cat. no. 560128) 
• Hoechst 33342 (Molecular probes, cat. no. H21492) 
• Mouse anti Myosin Heavy Chain antibody (Dilute 1:2; DSHB, cat. no. 
MF20) 
• Mouse anti Oct3/4  (Santacruz, cat. no. sc5279) 
• Rabbit anti Nanog (Abcam, cat. no. ab80892) 
• Rabbit anti Sox2 (Abcam, cat. no. ab97959) 
• Mouse anti human CD44, FITC (BD Biosciences, cat. no. 560977) 
• Mouse anti human CD56, APC (BioLegend, cat. no. 304610) 
• Mouse anti human CD31, FITC (Immunostep, cat. no. 31F-100T) 
• Mouse anti human CD13, FITC (ID Labs inc, cat. no. IDAC1071) 
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• Mouse anti human CD49b, FITC (BD Biosciences, cat. no. 555498) 
• Mouse anti human CD146, PE (Biocytex, cat. no. 5050-PE100T) 
• Mouse anti human CD45, PE (BD Biosciences, cat. no. 5555483) 
• Mouse anti human alkaline phosphatase, FITC (Santa Cruz, cat. no. 
217084) 
• Mouse anti human CD44, FITC (BD Biosciences, cat. no. 553133) 
• NBT/BCIP Stock Solution (Roche, cat. no.11681451001) 
• Trizma hydrochloride (Sigma, cat. no. T5941) 
• NaCl (Sigma, cat. no. S3014) 
• MgCl2 (Sigma, cat. no. M8266) 
• Tween 20 (Sigma, cat. no. P9416) 
• Immunodeficient adult mice (e.g., scid/beige, NOD or NSG strains) from 
an authorised facility and kept in a specific pathogen-free environment 
o CAUTION: any experiment involving animal work must be carried in 
accordance to specific regulations that vary across countries and 
institutions. Once the authorisation for animal work is granted, we 
advise to follow the “Guidelines for the welfare and use of animals 
in cancer research”41. 
 
Equipment 
• Cell culture 6-well plates (Nunc, cat. no. 140675) 
• Cell culture 12-well plates (Nunc, cat. no. 150628) 
• Cell culture T25 flask (Nunc, cat. no. 156367) 
• Cell culture T75 flask (Nunc, cat. no. 156499) 
• 35 mm x 10 mm cell culture dishes (Nunc, cat. no. 153066) 
• Cryovials (Corning, cat. no. 430488) 
• Cell counting slides with grids (Hycor, cat. no. 87144) 
• 30mm coverslips (Arlenfeld, cat. no. 0111700) 
• Sterile cell scrapers (Corning, cat. no. 3010) 
• Sterile 15 ml plastic tubes (Greiner Bio-one, cat. no.188271) 
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• Sterile 50 ml plastic tubes (Greiner Bio-one, cat. no.227261) 
• FACS tubes (BD Falcon, cat. no. 352063) 
• Sterile plastic pipettes (Corning, cat. no. 4486 / 4487 / 4488 / 4489) 
• Filtered tips (Corning, cat. no. 4810 / 4821 / 4823 /4809) 
• Pipettman (BD Falcon, cat. no. 357589) 
• Pipettes (Gilson, cat. no. F167300) 
• Centrifuge (Sigma, cat. no. 10360) 
• Cell incubator, 5% CO2 3-5% O2 (New Brunswick Scientific, cat. no. 
Galaxy 170R) 
• Phase contrast inverted microscope (Leica, cat. no. DMIL LED) 
• Fluorescence microscope (Leica, cat. no. DMI 6000B) 
• Flow cytometer (Beckman Coulter, CyAn ADP Analyzer) 
• Mister frosty freezing container (Nalgene, cat. no. 5100-0001) 
• -80°C freezer (New Brunswick Scientific, cat. no. U410-HEF) 
• Liquid nitrogen storage tank (Taylor Wharton, cat. no. LS6000) 
• 0.5 ml syringes for subcutaneous injection (BD, cat. no. 320927) 
• Vacuum filtering units (Corning, cat. no. 431097) 
• 40 µm cell strainer (Falcon, cat. no. 352340) 
• 500mL 0.22µm pore vacuum filters (cat. no. Corning 431097) 
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Reagents setup 
• Human bFGF: resuspend powder in sterile cell culture grade water at a 
final concentration of 100 ng / µl. Aliquot and store at -20°C.  
• Rock inhibitor Y27362: resuspend powder at a final concentration of 
1mg/ml. Aliquot and store at -20°C. Use diluted 1:300 in medium. 
• Matrigel: thaw the stock solution overnight on ice at 4°C and once liquid 
keep on ice and aliquot using cold tips and cold tubes. Store at -20°C. 
When needed, thaw on ice and dilute 1:100 in DMEM. 
• Geltrex: thaw the stock solution overnight on ice at 4°C and once liquid 
keep on ice and aliquot using cold tips and cold tubes. Store at -20°C. 
When needed, thaw on ice and dilute 1:100 in DMEM F12. 
• Iron Sulfate: stock solution is provided at 12.5 mg/ml (wt / vol). Dilute 
1:1000 in sterile water and use 530 µl / l. 
• Sodium Ferric Gluconate: stock solution is provided at 25 mg/ml (wt / vol). 
Dilute 1:1000 in sterile water and use 3.3 ml / l. 
• Oleic acid: prepare a stock solution dissolving the powder in sterile water 
at a concentration of 23.5 mg/ml (wt / vol), which is equal to 2.5 mM. 
Aliquot and store at -20°C. Use at the final concentration of 0.5 µM in 
medium. 
• Linoleic acid: prepare a stock solution dissolving the powder in sterile 
water at a concentration of 23 mg/ml (wt / vol), which is equal to 2.5 mM. 
Aliquot and store at -20°C. Use at the final concentration of 0.5 µM in 
medium. 
• iPS cell medium 
o KO DMEM  
o 25% (vol / vol) KSR 
o 1% (vol / vol) Non essential amino acids 
o 2 mM glutamine 
o 100 IU ml penicillin 
o 100 mg / ml streptomycin 
o 0.1 mM 2-Mercaptoethanol  
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o 10ng/ml human bFGF 
Filter complete medium with 0.22 µm pore vacuum filters  
• ES cell medium 
o KO DMEM  
o 20 % (vol / vol) KSR 
o 1 % (vol / vol) Non essential amino acids 
o 1 mM glutamine 
o 0.1 mM 2-Mercaptoethanol  
o 4 ng / ml human bFGF 
Filter complete medium with 0.22 µm pore vacuum filters.  
• Feeder-free iPS cell medium 
o Essential 8 basal medium 
o 1% (vol / vol) Essential 8 supplement 
Filter complete medium with 0.22 µm pore vacuum filters. 
• Dissociation medium 
o 0.5 mM EDTA 
o 1 % (vol / vol) FBS  
o 0.1 mM 2-Mercaptoethanol  
o PBS Calcium/Magnesium free  
Filter complete medium with 0.22 µm pore vacuum filters. 
• Commitment medium 
o MEM α, Nucleosides  
o 10 % (vol / vol) FBS  
o 2 mM glutamine 
o 100 IU / ml penicillin 
o 100 mg / ml streptomycin 
o 0.1 mM 2-Mercaptoethanol  
Filter complete medium with 0.22µm pore vacuum filters.  
• Proliferation medium 
o MegaCell DMEM 
o 5 % (vol / vol) FBS 
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o 100 IU / ml penicillin 
o 100 mg / ml streptomycin 
o 2 mM glutamine  
o 1 % (vol / vol) Non-essential amino acids 
o 0.05 mM 2-Mercaptoethanol  
o 5 ng / ml human bFGF 
Filter complete medium with 0.22 µm pore vacuum filters.  
• Alternative Proliferation medium (in case MegaCell DMEM is not available 
in your country or out of stock) 
o IMDM 
o 10% (vol / vol) FBS 
o 100 IU / ml penicillin 
o 100 mg / ml streptomycin 
o 2 mM glutamine  
o 1 % (vol / vol) Non-essential amino acids 
o 0.05 mM 2-Mercaptoethanol  
o 5ng / ml human bFGF 
o 0.5 µM Oleic Acid 
o 0.5 µM Linoleic Acid 
o 82.5 µg/L (wt / vol) Iron Sulfate  
o 6.625 µg/L (wt / vol) Sodium Ferric Gluconate 
Filter complete medium with 0.22 µm pore vacuum filters.  
• Differentiation medium 
o DMEM 
o 2 % (vol / vol) Horse Serum  
o 100 IU / ml penicillin 
o 100 mg / ml streptomycin 
o 2 mM glutamine  
Filter complete medium with 0.22µm pore vacuum filters.  
• Freezing medium 
o 90 % (vol / vol) FBS 
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o 10 % (vol / vol) DMSO 
Filter complete medium with 0.22µm pore vacuum filters.  
• Fluorescence activated cell sorting (FACS) buffer 
o PBS 
o 1% (vol / vol) FBS 
o 0.2 mM EDTA  
• 4-OH Tamoxifen: dissolve powder in ethanol at a stock concentration of 
25 mM and store at -20°C. Prior to use thaw an aliquot, dilute it to 250 µM 
with PBS and then dilute it 1:250 in fresh Differentiation Medium. 
• Collagenase IV: dissolve collagenase in KO DMEM at a final 
concentration of 1mg/ml. Aliquot and store at -20°C. 
• 4% (wt/vol) paraformaldehyde solution: dissolve 4g of paraformaldehyde 
into 100ml of PBS. Stir on the hot plate allowing the solution to warm up to 
60°C. Adjust the pH to 7.4 by adding 1N NaOH dropwise and wait until the 
solution is completely clear. Adjust the final volume with double distilled 
water. Aliquot and store at -20°C. Once thawed, working aliquots can be 
stored at 4°C for a week. 
o CAUTION: paraformaldehyde is extremely toxic and must be 
handled with adequate personal protective equipment under a 
chemical cabinet. 
• 2% (wt/vol) paraformaldehyde solution: Dilute 1:2 a required volume of 4% 
(wt/vol) paraformaldehyde solution with PBS. Aliquot and store at -20°C. 
Once thawed, working aliquots can be stored at 4°C for a week. 
o CAUTION: paraformaldehyde is extremely toxic and must be 
handled with adequate personal protective equipment under a 
chemical cabinet. 
• Phosphate buffered saline (PBS) for immunofluorescence: dissolve one 
tablet of PBS in 200ml of double distilled water. Stir until completely 
dissolved. 
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• Permeabilisation buffer for immunofluorescence (0.2% vol/vol Triton - 1% 
wt/vol BSA): dissolve 1 g of BSA in 100ml of PBS and stir well until 
dissolved. Add 200 µl of Triton and mix until dissolved. Store at 4°C. 
• Blocking buffer for immunofluorescence (10% vol/vol animal serum): dilute 
100 µl of animal serum in 900 µl of PBS (final volume 1 ml). 
• Animal serum for immunofluorescence: thaw at 4°C, aliquot and store at -
20°C. 
• Hoechst 33342: dissolve the dye in water at a final concentration of 10 
mg/ml, aliquot and store protected from light at 4°C. Use diluted 1:250. 
• Polybrene: Prepare a stock solution of 8 mg/ml by dissolving the required 
amount of powder in sterile water or PBS. Store solution protected from 
light at 4°C. Use at 1:1000 dilution in Proliferation Medium when 
transducing cells. 
• Trizma hydrochloride 1M: dissolve 15.76 g in 100 ml of double distilled 
water and adjust the pH to 5.5. Store at room temperature (our laboratory 
has an average room temperature of 20±2°C). 
• NaCl 1M: dissolve 5.49 g in 100 ml of double distilled water. Store at room 
temperature. 
• MgCl2 1M: dissolve 9.52 g in 100 ml of double distilled water. Store at 
room temperature for maximum 1 month. 
o CAUTION: the reaction is exothermic: use a large container when 
dissolving powder to avoid spilling of the solution. 
• Tween 20 20% (vol/vol): dissolve 2 ml of Tween 20 in 18 ml of double 
distilled water. Store at room temperature in a glass container. 
• Alkaline phosphatase staining solution: for each 35 mm dish to be stained 
for alkaline phosphatase via enzymatic reaction, prepare 1 ml of staining 
solution by mixing 100 µl of Trizma hydrochloride 1 M, 100 µl of NaCl 1 M, 
50 µl of MgCl2 1M, 5 µl Tween 20 20% (vol / vol), 725 µl of double distilled 
water and 20 µl of NBT/BCIP stock solution. Prepare a fresh solution for 
each staining. 
o CAUTION: the solution is light sensitive. 
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Antibody Working dilution Example of positive control 
Anti Oct4 1:100 Human iPS/ES cells 
Anti Sox2 1:200 Human iPS/ES cells 
Anti Nanog 1:100 Human iPS/ES cells 
Anti SSEA4 1:25 Human iPS/ES cells 
Anti CD44 1:100 Human leucocytes 
Anti CD56 1:50 Human myoblasts 
Anti CD31 1:125 HUVEC 
Anti CD13 1:125 HUVEC 
Anti CD49b 1:25 Human lymphocytes 
Anti CD146 1:10 HUVEC 
Anti CD45 1:25 Human leucocytes 
Anti alkaline phosphatase 1:100 HeLa cells 
Anti myosin heavy chain 1:2 Differentiated myoblasts 
 
Table 1. Working dilutions of antibodies and possible positive controls. 
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Equipment setup  
• Matrigel-coated plates: thaw an aliquot of Matrigel on ice and once 
liquefied, dilute it 1:100 in ice-cold DMEM with a cold pipette tip. Mix 
throughout and put 1 ml of diluted Matrigel solution in each 35 mm dish or 
well of a 6-well plate. Shake the plate gently in order to cover the whole 
surface with Matrigel. Incubate at 37°C for 30 minutes and then remove 
the residual Matrigel without scraping the bottom of the well. Wash twice 
with DMEM or PBS. For immediate use, plate cells in the appropriate 
medium. For later use, cover the well with 1ml of DMEM and put back in 
the incubator at 37°C. Coated plates should be used on the day of 
preparation. 
o CRITICAL STEP: undiluted Matrigel solidifies above 4°C. It is 
therefore important to thaw it on ice and dilute it in ice-cold medium 
with a cold pipette tip. 
• Geltrex-coated plates: thaw an aliquot of Geltrex on ice and once 
liquefied, dilute it 1:100 in ice-cold DMEM F12 with a cold pipette tip. Mix 
throughout and put 1 ml of diluted Geltrex solution in each 35 mm dish or 
well of a 6-well plate. Shake the plate gently in order to cover the whole 
surface with Geltrex. Incubate at 37°C for 60 minutes and then remove 
Geltrex without scraping the bottom of the well. For immediate use, plate 
cells in the appropriate medium. For later use, wrap with Parafilm and 
store at 4°C for up to two weeks. 
o CRITICAL STEP: undiluted Geltrex solidifies above 4°C. It is 
therefore important to thaw it on ice and dilute it in ice-cold medium 
with a cold pipette tip. 
• Gelatin-coated plates: add 1.5 ml of EmbryoMax 0.1% (wt/vol) Gelatin 
solution to each well of a 6-well plate and incubate at room temperature 
for 30 minutes. Discard solution and immediately add cells resuspended in 
medium. 
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PROCEDURE 
 
Steps 1-40: From pluripotent cells to mesoangioblast-like cells 
Timing: 18-21 days  
Single cell dissociation of pluripotent cell colonies and early commitment 
1 For a successful outcome, ES/iPS cell cultures must be homogeneous with 
no differentiated cells contaminating the dish. Start the protocol when the 
colonies population are at a confluency of about 70%, ideally with 1-3 wells 
of a 6-well plate. 
o CRITICAL STEP: if a minimal proportion of differentiated cells is present 
in the culture, they need to be manually selected and removed prior to 
the start of the differentiation procedure.  
2 In order to increase single-cell survival after dissociation, pre-treat ES/iPS 
cells with 10 mM ROCK inhibitor adding it to the cell culture medium. 
Incubate for 1 hour at 37°C.  
3 Prepare a 35 mm dish coated with 1% vol / vol growth factor–reduced 
Matrigel as described in the Equipment setup. 
4 Remove the medium with ROCK inhibitor from the plates and gently wash 
the ES/iPS cells with 2 ml Ca2+-Mg2+-free PBS. 
5 Add 1 ml of pre-warmed Dissociation Medium to each ES/iPS cell well and 
incubate at 37°C for 10 minutes. 
6 Shake plates gently by tapping on their side in order to facilitate dissociation 
of colonies. Inspect the plates and look for floating cells.  
A. Feeder-dependent cultures: aim to detach most of the colonies at the 
expense of feeder cells, which will remain attached to the plastic. The 
first incubation is usually not enough to detach all the cells so put the 
plates back in the incubator and repeat step 6 every 15 minutes for up to 
2 hours. Move to the next step when most of the colonies detached as 
single cells or little clumps. 
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o CRITICAL STEP: do not keep the cells in Dissociation Medium for 
more than 2 hours total as this decreases cell survival and 
compromises the following steps of the protocol. 
B. Feeder-free cultures: iPS cells cultured in feeder-free condition detach 
very easily from the dish after 15 minutes of incubation at 37°C. No 
further incubation should be required. 
7 Collect Dissociation Medium with the detached cells in a 15 ml sterile tube. 
Gently resuspend the cells with a P1000 tip to facilitate disaggregation of 
clumps.  
o CRITICAL STEP: in case of feeder-dependent cultures, make sure not to 
scrape the bottom of the dish in order not to detach feeder cells. 
8 Add at least 1 volume of pre-warmed Commitment Medium to the tubes to 
dilute Dissociation Medium. 
9 Centrifuge cell suspension at 232g for 5 minutes.  
10 Discard supernatant, resuspend the pellet in pre-warmed Commitment 
Medium and count cells.  
o CRITICAL STEP: in order to plate the appropriate number of cells, it is 
important to evaluate cell viability through a vital staining, such as Trypan 
blue. 
11 Wash twice the Matrigel-coated dish with DMEM or PBS and plate cells 
according to option A (feeder-dependent cultures) or B (feeder-free cultures): 
A. Feeder-dependent cultures: plate 6 x 104 cells / cm2, which is 
approximately 6 x 105 cells for a 35 mm dish 
? TROUBLESHOOTING 
B. Feeder-free cultures: plate 3 x 105 cells / cm2, which is approximately 3 x 
106 cells for a 35 mm dish. 
12 Incubate the plate at 37°C with 5% CO2 and 3 to 5% O2. 
13 Replace Commitment Medium the next day in order to eliminate dead cells. 
14 Inspect the plate daily and replace Commitment Medium every 2-3 days with 
pre-warmed fresh Commitment Medium. 
15 Move to the following step after 1 week. 
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Intermediate commitment and adaptation to a reduced cell density 
16 Prepare a 35 mm dish coated with 1% vol / vol growth factor–reduced 
Matrigel as described in the Equipment setup. 
17 Dissociate the cell culture with pre-warmed Dissociation Medium as detailed 
in points 3-6. Additional gentle scraping of the dish surface can be performed 
if cells do not detach completely after a maximum of 2 hours in Dissociation 
Medium. 
? TROUBLESHOOTING 
18 Collect the cells in Dissociation Medium in a 15 ml tube and gently 
resuspend them with a P1000 tip. Add 1 volume of pre-warmed Commitment 
Medium. 
19 Filter the cell suspension with a 40 µm cell strainer placed on a collection 
tube in order to remove aggregates. 
20 Centrifuge filtered cell suspension at 232g for 5 minutes. 
21 Discard the supernatant, resuspend the pellet in pre-warmed Commitment 
Medium and count cells.  
o CRITICAL STEP: in order to plate the appropriate number of cells, it is 
important to evaluate cell viability through a vital staining, such as Trypan 
blue. 
22 Wash twice the Matrigel-coated dish with DMEM or PBS and plate 2.5 x 104 
cells / cm2 (approximately 2.5 x 105 cells for a 35 mm dish). 
? TROUBLESHOOTING 
23 Incubate cells at 37°C with 5% CO2 and 3 to 5% O2. 
24 Inspect the plate daily and replace Commitment Medium every other day with 
fresh pre-warmed medium.  
? TROUBLESHOOTING 
25 Move to the following step after 1 week. 
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Late commitment: high-density culture and adaptation to trypsin dissociation 
26 Prepare a 35 mm dish coated with 1% (vol / vol) growth factor–reduced 
Matrigel as described in the Equipment setup. 
27 Wash the plate with the cells with 2 ml PBS and add 0.5 ml of trypsin to 
detach them. Incubate plates at 37°C with 5% CO2 and 3 to 5% O2 for 5 
minutes. 
28 Remove cells from the incubator and shake plate to facilitate cell 
detachment. Inspect under the microscope. When all the cells have 
detached, block trypsin activity with pre-warmed Commitment Medium. 
Resuspend with a pipette and collect the cell suspension. 
29 Centrifuge cell suspension at 232g for 5 minutes. 
30 Discard supernatant, resuspend the pellet in pre-warmed Proliferation 
Medium and count cells.  
o CRITICAL STEP: in order to plate the appropriate number of cells, it is 
important to evaluate cell viability through a vital staining, such as Trypan 
blue. 
31 Wash twice the Matrigel-coated dish with DMEM or PBS and plate 2 x 104 
cells / cm2 (approximately 2 x 105 cells for a 35 mm dish or at confluence of 
80%).  
32 Incubate cells at 37°C with 5% CO2 and 3 to 5% O2. 
33 Inspect cells daily and replace medium every other day. 
34 Move to the next step after 3 days at 100% confluence. 
 
HEDEM/HIDEM cultures stabilisation 
35 Detach cells by trypsinization as described in points 27-28. 
36 Centrifuge cell suspension at 232 g for 5 minutes. 
37 Discard the supernatant, resuspend the pellet in pre-warmed Proliferation 
Medium and count cells. 
38 Plate 1.2 x 104 cells / cm2 on cell culture plastic without any coating. 
 28 
39 Incubate cells at 37°C with 5% CO2 and 3 to 5% O2. 
40 Inspect the cells daily and split the culture by trypsinisation as they reach 
80% confluence. Different lines differ in proliferation rate but generally 
cultures require splitting every 3-4 days. The cell population at this step is 
regarded as HEDEMs/HIDEMs passage zero (p0). From now onwards, cells 
are cultured like bona fide mesoangioblasts35. The cells can now be 
expanded and cryopreserved. 
 
Step 41-44: Expansion of HEDEMs/HIDEMs 
Timing: minimum 7-10 days (depending on the number of cells required) 
41 HEDEM/HIDEM cultures require splitting when the culture is roughly 80% 
confluent. On the day of splitting, wash plates once with PBS, add a volume 
of trypsin necessary to cover the whole culture surface and incubate cells at 
37°C for 5 minutes. 
42 Shake plate to facilitate cell detachment and inspect them under the 
microscope. When all the cells are detached add pre-warmed Proliferation 
Medium to block trypsin activity. Resuspend and collect cells in a tube for 
centrifugation. 
43 Centrifuge cell suspension at 232 g for 5 minutes. 
44 Discard the supernatant, resuspend the pellet in pre-warmed Proliferation 
Medium and count cells. Plate 1.2 x 104 cells / cm2. Cells generally require a 
splitting ratio of 1:3 - 1:6 depending on the cell line. 
 
Step 45-50: Cryopreservation of HEDEMs/HIDEMs 
Timing: 1 hour 
From passage zero, HEDEMs/HIDEMs can be cryopreserved. It is highly 
recommended to cryopreserve a stock of cells at low passages (p0-3) and, if 
possible, it is good practice to freeze one vial of cells or more at each passage. 
45 Fill the lower chamber of a Nalgene freezing container with isopropanol and 
pre-chill the container at 4°C. 
46 When cell culture reaches 80% confluency, detach cells as detailed in points 
41-43. 
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47 Discard the supernatant and any residual medium left in the tube. 
48 Disrupt the cell pellet by gentle tapping at the bottom of the tube. 
49 Resuspend the pellet in 1ml of cold freezing medium, transfer to a labelled 
cryovial and immediately put vial in a freezing container. 
50 Put freezing container at -80°C. For long-term storage, transfer vial in a liquid 
nitrogen storage tank. 
 
Step 51-73: Characterisation of HEDEMs/HIDEMs 
Timing: 1 day for FACS analysis, 1 day for immunofluorescence staining 
After derivation, HEDEMs/HIDEMs should be characterised by flow cytometric 
analysis (51-61) to assess the expression of a panel of pericyte/mesoangioblast 
markers and by immunofluorescence to confirm the absence of any residual 
pluripotency marker (62-73). 
 
Immunophenotype analysis by flow cytometry 
51 Wash cells with PBS and add trypsin to detach them. Incubate plates at 37°C 
with 5% CO2 and 3 to 5% O2 for 5 minutes. 
52 Remove cells from the incubator and shake plate to facilitate cell 
detachment. Inspect under the microscope. When all the cells have 
detached, block trypsin activity with FACS buffer. Resuspend with a pipette 
and collect the cell suspension.  
53 Filter cells through a 40 µm (pores’ size) cell strainer and count them.  
54 Place appropriate cell number in single centrifuge-proof FACS tubes. Usually 
at least 1 x 105 cells are used for each antibody staining and for unstained 
controls. 
55 Centrifuge the tubes at 232g for 5 minutes. 
56 Discard supernatant, gently resuspend pellet in 2 ml of FACS buffer for a 
wash and centrifuge at 232g for 5 minutes. 
57 Discard the supernatant and gently tap the cell pellet to resuspend it in 50 µl 
of FACS buffer in the tube. 
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58 Leave unstained control tubes on ice and set aside until FACS read. In 
parallel add staining antibodies to samples at the dilution described in the 
reagents list section and incubate at 4°C in the dark for 45 minutes. 
59 Add 3 ml of FACS buffer to samples to wash unbound antibody and 
centrifuge the tubes at 232g for 5 minutes. 
o PAUSE POINT: at this point you can either analyse samples immediately 
or you can fix them with 2% (wt / vol) paraformaldehyde, protecting them 
from light and storing them at 4°C. Samples can be analysed up to three 
days later. 
60 Discard supernatant and resuspend cells in the appropriate volume for 
analysis.  
61 Perform FACS analysis. 
o CRITICAL STEP: if you are not familiar with the FACS device ask facility 
operators for suggestions on laser and compensation settings, especially 
if you are working with genetically manipulated fluorescent cells (e.g. 
GFP-positive cells).  
 
Assessment of residual pluripotency markers  
62 Plate four 35 mm dishes with 1 x 105 HEDEMs/HIDEMs each in Proliferation 
Medium. 
o CRITICAL STEP: it is important to have a dish of pluripotent cells from 
which HEDEMs/HIDEMs were derived to use as a positive control. 
63 24 hours after plating remove Proliferation Medium and wash twice with PBS. 
64 Fix plates with 4% wt / vol paraformaldehyde for 10 minutes at RT 
o CAUTION: Paraformaldehyde is extremely toxic and must be handled 
under a chemical cabinet. 
o PAUSE POINT: fixed cells can be kept with PBS at 4°C for at least two 
weeks before proceeding with the staining. 
65 Permeabilise cells with PBS - 0.2% vol / vol Triton - 1% wt / vol BSA for 30 
minutes at room temperature. 
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66 Remove permeabilising solution and incubate with 10% vol / vol animal 
serum for 30 minutes at room temperature to block non-specific binding sites. 
67 Remove animal serum and incubate one dish with anti-Sox2, one with anti-
Oct4 and one with anti-Nanog primary antibody for 1 hour at room 
temperature.  
o CRITICAL STEP: we advise to use the remaining dish to assess 
potential non-specific binding of the secondary antibody to the sample 
and to evaluate an eventual level of background. This can be done by 
incubating the dish with just the secondary antibody and the nuclear dye. 
68 Perform three washes of 5 minutes with PBS - 0.2% vol / vol Triton to 
remove unbound antibody. 
69 Incubate dish with the appropriate secondary antibody conjugated with a 
fluorochrome of choice diluted in PBS - 0.2% vol / vol Triton - 1% wt / vol 
BSA at room temperature for 1 hour. In the same incubation also 
counterstain the nuclei with a nuclear dye such as Hoechst. 
70 Perform two washes of 5 minutes with PBS - 0.2% vol / vol Triton to remove 
unbound antibody and one wash of 5 minutes with PBS. 
71 Carefully aspirate the last PBS wash from the dish and add 1 drop of 
fluorescence mounting medium. 
72 Put a coverslip on top of the dish to protect the specimen and avoid 
evaporation. 
73 Image cells under a fluorescence microscope equipped with filters for the 
nuclear dye and the secondary antibody of choice. 
 
Step 74-99: Myogenic differentiation induction 
Timing: 1 day for transduction, 7 days for expansion of transduced cells, 8 
days for differentiation, 1 day for immunofluorescence staining 
HEDEMs/HIDEMs lentiviral transduction with MyoD-ER(T) 
74 Plate 1 x 105 HEDEMs/HIDEMs in a 35 mm dish in Proliferation Medium. 
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75 When the cells are fully attached to the culture dish, thaw the MyoD-ER(T) 
lentiviral vector on ice and calculate the volume necessary to transduce cells 
with a multiplicity of infection (MOI) of 1, 10 and 50.  
76 The following formula can be used at this purpose:   
µl of virus needed = number of cells to infect x desired MOI / number of cells 
to infect x desired MOI 
o CAUTION: work involving the use of viral vectors must be carried under 
a class two cabinet. Appropriately inactivate any residual lentiviral vector 
particles on surfaces and liquids that went in contact with it before their 
disposal.  
o CRITICAL STEP: Titrate the MOI in order to find the amount of lentiviral 
vector that allows the cell culture to differentiate in myosin heavy chain 
(MyHC)-positive myotubes with an efficiency > 50 %. Differentiation 
efficiency can be assessed only after transduction. We suggest 
performing experiments with the cells that have the highest differentiation 
efficiency to MOI rate (i.e. the best differentiation with the lowest amount 
of lentiviral vector). 
77 Dilute the lentiviral vector in 1 ml of Proliferation medium supplemented with 
1µl of Polybrene. 
78 Remove medium from the 35 mm dish of MyoD-ER(T)-HEDEMs/HIDEMs 
and replace it with the 1 ml of viral suspension. Incubate the cells for 12 
hours at 37°C with 5% CO2 and 3 to 5% O2. 
79 Remove medium and wash plate twice with PBS. Put fresh Proliferation 
Medium on cells. 
80 Incubate the cells at 37°C with 5% CO2 and 3 to 5% O2 and inspect daily. 
81 Expand cells as described in steps 41-44. 
 
Differentiation assay and immunofluorescence for myosin heavy chain 
82 Prepare Matrigel-coated 35 mm dishes. 
83 Plate 1.5/2 x 105 MyoD-ER(T)-HEDEMs/HIDEMs on a Matrigel-coated dish. 
84 Incubate cells in growth medium at 37°C with 5% CO2 and 3 to 5% O2. 
 33 
85 Check cells daily and add 1 mM 4OH-Tamoxifen to Proliferation Medium 
when cells reach 90-100 % confluence. 
86 After 24 hours, replace Proliferation Medium with fresh Differentiation 
Medium supplemented with 1 mM 4OH-Tamoxifen.  
87 Inspect cultures daily for myotubes formation. Replace half of the 
Differentiation Medium daily. Myotubes are usually identifiable in culture 
starting from 3 after the first Tamoxifen addition.  
o CRITICAL STEP: differentiated cultures are delicate as myotubes detach 
easily when the plates are not handled gently. Media change should be 
done slowly and the medium should be added drop by drop on the 
sidewall of the plate. 
88 From 6 to 7 days after the second Tamoxifen administration and the switch 
to Differentiation Medium the cell culture should be predominantly 
composed of multinucleated myotubes. These cultures are now ready to be 
analysed. Wash the differentiated plate gently with PBS twice and fix it with 
4% wt / vol paraformaldehyde for 10 minutes at RT. 
o CAUTION: Paraformaldehyde is extremely toxic and must be handled 
under a chemical cabinet. 
o PAUSE POINT: fixed cells can be kept with PBS at 4°C for at least two 
weeks before proceeding with the staining. 
89 Permeabilise cells with PBS - 0.2% vol / vol Triton - 1% wt / vol BSA for 30 
minutes at room temperature. 
90 Remove permeabilising solution and incubate with 10% vol / vol animal 
serum for 30 minutes at room temperature to block non-specific binding 
sites. 
91 Remove animal serum and incubate the dish with anti-myosin heavy chain 
(MyHC) primary antibody for 1 hour at room temperature.  
o CRITICAL STEP: another differentiated dish or a sector of the same 
dish needs be incubated with secondary antibody and nuclear dye 
alone and hence used to assess the eventual non-specific binding of 
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the secondary antibody to the sample and to evaluate the eventual level 
of background.  
92 Perform three washes of 5 minutes with PBS - 0.2% vol / vol Triton to 
remove unbound antibody. 
93 Incubate dish with any anti-mouse secondary antibody conjugated with a 
fluorochrome of choice diluted 1:500 in PBS - 0.2% vol / vol Triton - 1% wt / 
vol BSA at room temperature for 1 hour. In the same incubation also 
counterstain the nuclei with a nuclear dye such as Hoechst (1:250). 
94 Perform two washes of 5 minutes with PBS - 0.2% vol / vol Triton to remove 
unbound antibody and one wash of 5 minutes with PBS. 
95 Carefully aspirate the last PBS wash from the dish and add 1 drop of 
fluorescence mounting medium. 
96 Put a coverslip on top of the dish to protect the specimen and avoid 
evaporation. 
97 Image cells with a fluorescent microscope equipped with filters for the 
nuclear dye and the secondary antibody of choice. Take at least 10 random 
field pictures of the stained dish, using a microscope equipped with a 20X 
magnification lens (total magnification 200X).  
98 Merge nuclear dye images with MyHC images and count the total number of 
nuclei. Then count only the number of nuclei localized within MyHC positive 
myotubes. 
99 Apply the following formula to obtain the differentiation efficiency percentage: 
Number of nuclei within MyHC positive myotubes x 100 / Total number of 
nuclei of the field 
 
Step 100-107: Tumour formation assay to test in vivo safety profile  
Timing: 2 hours for cell injection and 4 months minimum follow up 
(depending on specific animal regulations) 
100 Detach the cells by trypsinization as described in points 41-43. 
101 Discard the supernatant, resuspend the cell pellet by tapping at the bottom 
of the tube and resuspend it in at least 10 ml of PBS. 
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102 Centrifuge cell suspension at 232 g for 5 minutes. 
103 Discard the supernatant and resuspend pellet in PBS to a final 
concentration of 2x106 cells / 150 µl (the volume of each injection).  
104 Bring cells to the room designated for animal work and prepare mice for 
procedure according to your animal licence. 
o CRITICAL STEP: all the animal work must obtain ethical approval and 
needs to be carried out in accordance to the animal regulation of your 
country and institution.  
105 Inject 150 µl of the cell suspension subcutaneously in the back or in the 
dorsal flank of immunodeficient mice (e.g., scid/beige, NOD or NSG strains). 
HeLa cells can be used as a positive control for tumour formation. 
106 Screen the animals twice a week for the presence of growing sub-
cutaneous masses. A minimum follow-up (followed by necropsy) of 4 months 
is highly recommended.  
o CRITICAL STEP: monitor mice closely for clinical signs associated with 
tumour growth necessitating immediate culling (e.g., cachexia, 
dehydration, ulceration, infection). 
107 In case of tumour mass formation of more than 10 mm of diameter, 
proceed to humanely kill the animal in order not to cause pain or significant 
discomfort.  
 
TIMING 
 
Steps 1-40: From pluripotent cells to mesoangioblast-like cells 18-21 days 
Step 41-44: Expansion of HEDEMs/HIDEMs minimum 7-10 days (depending 
on the number of cells required) 
Step 45-50: Cryopreservation of HEDEMs/HIDEMs 1 hour 
Step 51-73: Characterisation of HEDEMs/HIDEMs 1 day for FACS analysis, 1 
day for immunofluorescence staining  
Step 74-99: Myogenic differentiation induction 1 day for transduction, 7 days 
for expansion of transduced cells, 8 days for differentiation, 1 day for 
immunofluorescence staining  
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Step 100-107: Tumour formation assay to test in vivo safety profile 2 hours 
for cell injection and 4 months minimum follow up (depending on specific animal 
regulations) 
TROUBLESHOOTING TABLE 
Step Problem Possible reason Possible solution 
11 
and 
22 
Poor cell 
survival. 
Some human 
ES/iPS cell 
cultures are 
more sensitive 
to single-cell 
passaging. 
Seed higher cell concentrations 
(e.g., 2X, 3X and 5X) to prevent 
sub-optimal cell density due to poor 
cell survival. It is advisable to 
continue the protocol with the plate 
that had the best survival and hence 
appropriate density the day after 
plating. 
17 Cells do not 
detach after 2 
hours in 
dissociation 
media. 
Some HIDEMs 
lines strongly 
adhere to the 
Matrigel coating 
making difficult 
to detach them. 
Collect the dissociation media 
containing the cells that have 
already detached from the dish, 
wash the dish once with PBS and 
perform a short trypsinization at 
37°C (2-3 minutes). Collect the cell 
and proceed to step 18. 
24 The culture 
appears 
heterogeneous 
with cell of 
different 
morphologies 
coexisting in 
the same dish. 
In feeder-
dependent 
cultures some 
residual 
inactivated 
feeder-layer 
cells might be 
carried into this 
step. 
No action is required: inactivated 
feeder layer cells are gradually lost 
in the following steps and the 
culture will become homogenous. 
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ANTICIPATED RESULTS 
 
The protocol discussed here enables the efficient derivation of expandable 
mesoangioblast-like cells from both human ES and iPS cells (respectively 
HEDEMs and HIDEMs) that can then be easily differentiated into skeletal muscle 
cells (see Figure 1 for a schematic overview of the entire method). The derivation 
of HEDEMs/HIDEMs entails different steps, from pluripotent colonies to single 
cells resembling mesoangioblasts, which can be expanded before or after 
transduction with a Tamoxifen-regulated MyoD cassette. Figure 2 shows 
representative images of the morphology of the cell cultures at the different steps 
of the protocol.  
HEDEMs/HIDEMs are characterised by a good proliferation potential with 
some cell lines able to generate over a period of 30 days up to 1012 cells starting 
from 5 x 105 (see Figure 3). A decreased proliferation rate might be observed 
upon MyoD-ER(T) transduction but still MyoD-ER(T)-HEDEMs/HIDEMs are 
capable of a significant expansion. This expansion potential supports the 
theoretical feasibility of translating this iPS cell-based approach to possible 
clinical settings, where billion cells per patient might be required and where cell 
availability/expansion is often a major bottleneck. We observed a slight decrease 
in proliferation of feeder-free HIDEMs compared with feeder-dependent HIDEMs 
derived from the same iPS cell colonies. However fewer lines were tested in 
comparison with feeder-dependent cultures, therefore this observation might be 
related to variability normally existing amongst different cell lines. Nonetheless, 
possible issues of reduced proliferation could always be overcome by increasing 
the amount of colonies in the starting iPS cell populations.  
HEDEMs/HIDEMs express surface markers that can be assessed by 
means of fluorescence activated cell sorting as shown in Figure 4. In detail, 
HEDEMs/HIDEMs express CD146 (a perivascular marker), CD13, CD49b and 
CD44. AP, a marker of a subpopulation of skeletal muscle pericytes, shows 
variable expression levels amongst different cell lines. In addition, it is possible to 
evaluate more accurately AP activity via enzymatic reaction as shown and 
described in Supplementary Figure 1b. Notably, even though some cell lines 
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express low AP levels, this does not affect the quality of the final product 
provided that other markers (e.g. CD146, CD13, CD44, CD49b) and parameters 
(e.g. in vitro differentiation assays) are met. Cells have to be negative or only 
weakly positive for CD56, SSEA4 and CD31. Representative percentages of 
positivity for all the different markers quoted above are shown in Supplementary 
Table 1.  Furthermore, HEDEMs/HIDEMs do not display any significant residual 
expression of pluripotency-associated markers and this can be easily detected by 
an immunofluorescence analysis for Sox2, Nanog and Oct4 expression 
(Supplementary Figure 1a).   
Once HEDEMs/HIDEMs have been characterised for their surface 
markers, they can be differentiated into multinucleated skeletal myotubes. To this 
aim, the use of a Tamoxifen-activated MyoD (MyoD-ER(T)) synchronises the 
differentiation of the whole culture. In order to obtain optimal results in terms of 
both cell proliferation and skeletal muscle differentiation, it is good practice to 
titrate the multiplicity of infection (MOI) of the MyoD-ER(T) lentiviral vector for 
every newly generated line. You should aim at having a differentiation efficiency 
of at least 50% of the total population (although we have observed differentiation 
efficiency above 90% with lines infected with a MOI < 5). Representative images 
of differentiated HEDEM/HIDEM lines can be found in Figure 5. The 
differentiation efficiency of each line is calculated by counting the number of 
nuclei inside MyHC positive cells over the total number of nuclei in at least ten 
randomly selected fields of the differentiated dishes (20X magnification; 
Supplementary Table 2). The ratio, expressed as percentage, is an index of the 
differentiation efficiency of the examined cell line. We have also incidentally 
observed formation of sarcomeric striations and spontaneous twitching of 
myotubes derived from HIDEMs after 8 days in myogenic differentiation medium 
(Supplementary Video 1). However, as this is not observed frequently, we do not 
rely on these parameters to monitor the efficiency of the protocol, which indeed is 
best achieved by using MyHC immunofluorescence staining. 
Tumorigenic assays and transplantation experiments of HEDEMs/HIDEMs 
in immunodeficient mice demonstrate that the procedure is safe. For all the cell 
 39 
lines tested, no tumours were found after a minimum of 4 months follow-up. 
Assessment of regenerative potential of the final product is then performed by 
cell transplantation in mouse models of muscle regeneration, as recently detailed 
in a specific video-protocol14. 
 
 
FIGURE LEGENDS 
 
Figure 1. Workflow of the protocol to generate myogenic cells from human 
pluripotent stem cells via differentiation into mesoangioblast-like cells and 
transient MyoD activation. 
 
Figure 2. Representative images showing the expected cell morphology 
along the protocol. Phase contrast pictures displaying cell morphology starting 
from pluripotent colonies (left column), through the various steps of the protocol 
(middle columns) until the final product. The established HIDEM/HEDEM cell 
lines are shown in the right column. (Scale bar 100 µm). 
 
Figure 3. Representative number of cells obtained in one month of culture. 
The bar graph depicts the total number of cells derived from culturing healthy 
donor, disease-specific (LGMD2D and DMD) HIDEMs and HEDEMs over a 
period of 30 days, starting from 5x105 cells (log 10 scale, each line in duplicate). 
LGMD2D: limb girdle muscular dystrophy 2D; DMD: Duchenne muscular 
dystrophy. Please note that DMD HIDEMs were also genetically corrected with a 
human artificial chromosome containing the human dystrophin genetic locus 
(DYS-HAC)11,50. 
 
Figure 4. Analysis of HEDEM/HIDEM surface markers by flow cytometry. 
The panel shows representative flow cytometry histograms of HIDEMs (left 
column), FF HIDEMs (middle column) and HEDEMs (right column). The 
histograms of unstained controls are shown in black whereas the samples 
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stained with fluorochrome-conjugated antibodies are overlaid in red. A minimum 
number of 104 events are shown for each histogram. 
 
Figure 5. Myogenic differentiation of HEDEMs/HIDEMs with MyoD-ER(T). 
The panel shows four different lines of HIDEMs and one line of HEDEMs 
differentiated into skeletal myotubes after administration of two pulses of 4OH-
Tamoxifen, assessed by immunofluorescence staining for myosin heavy chain 
(MyHC). The top row shows nuclei stained with Hoechst; differentiated myotubes 
are shown in the middle row. The lower part of the panel shows the merged 
images used to quantify the efficiency of differentiation (detailed in 
Supplementary Table 2; scale bar 75 µm). 
 
SUPPLEMENTARY INFORMATION 
 
Supplementary Figure 1. Additional cell characterisation: pluripotency 
analysis and alkaline phosphatase staining. (a) Representative 
immunofluorescence staining for the pluripotency factors Nanog, Oct4 and Sox2. 
Feeder-free HIDEMs are negative for all the markers and are shown in the left 
part of the panel. On the right hand side, stained feeder-free iPS cells are shown 
as positive control (scale bar 50 µm). (b) The histogram on the left hand side 
shows absence of AP signal in one HIDEM line, whereas the picture on the right 
had side shows AP activity detected with enzymatic reaction (purple/black 
precipitate; scale bar 50 µm). 
 
Supplementary Video 1. The video shows a myotube derived from differentiated 
DMD HIDEMs twitching in culture at day 8 in myogenic differentiation medium. 
Sarcomeric striations are visible in their characteristic structure of alternate dark 
and light bands (640X magnification). 
 
 
Protocol for alkaline phosphatase staining (Supplementary figure 1b) 
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• Fix dishes of HEDEMs/HIDEMs with 4% (wt/vol) paraformaldehyde 
solution for 5 minutes at room temperature. Wash once with PBS, add 1ml 
of alkaline phosphatase staining solution and incubate in the dark at room 
temperature. Wait for the development of the reaction protecting it from 
light. Check under inverted microscope for the appearance of the staining 
every 15 minutes up to 2 hours of incubation with staining solution. 
Consider the use of paraformaldehyde-fixed HeLa cells as positive control 
for the reaction. 
 
 
 
 
Marker 
Percentage of positive cells 
HIDEMs FF HIDEMs HEDEMs 
CD13 99.9% 73.3% 70.4% 
CD31 0% 4.4% 0.1% 
CD44 99.7% 98.3% 99.8% 
CD45 0.3% 4.9% 0.4% 
CD49b 99.9% 90.7% 99.8% 
CD56 0.3% 1.6% 0.5% 
CD146 84.8% 78.7% 99.2% 
SSEA4 0.9% 6.3% 1.5% 
 
Supplementary Table 1. Quantification of FACS analysis. The table displays 
the percentage of cells (HIDEMs, FF HIDEMs and HEDEMs, presented in Figure 
4) positive for different surface marker expression analysed by FACS. The 
percentages were calculated gating and subtracting the unstained sample from 
the stained one.  
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Cell line 
Nuclei 
outside 
MyHC+ 
cells 
Nuclei 
inside 
MyHC+ 
cells 
Total 
number of 
nuclei 
Calculated 
efficiency of 
differentiation 
HIDEMs 35 101 136 74.3% 
DMD HIDEMs 76 268 344 77.9% 
LGMD2D HIDEMs 13 155 168 92.3% 
FF HIDEMs 0 181 181 100% 
HEDEMs 50 175 207 75.1% 
 
Supplementary Table 2. Quantification of myogenic differentiation. 
Representative results obtained by counting the single images of the different 
lines shown in Figure 5. Nuclei outside and inside MyHC-positive cells are 
counted and then the ratio of nuclei inside MyHC-positive cells / total nuclei is 
used to calculate the differentiation efficiency.  
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